<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="502">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300495</url>
  </required_header>
  <id_info>
    <org_study_id>2005P000376</org_study_id>
    <nct_id>NCT00300495</nct_id>
  </id_info>
  <brief_title>Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection</brief_title>
  <official_title>Phase III Study of Preoperative Amiodarone for Prevention of Atrial Fibrillation After Lung Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation is a very common complication of pulmonary resection. Patients who
      develop atrial fibrillation require additional treatment and are more likely to stay in the
      hospital for longer period of time increasing the costs associated with the operation. We
      propose a randomized controlled trial to see if oral amiodarone given for one week before
      surgery can prevent atrial fibrillation after pulmonary resection. We plan to evaluate the
      incidence of atrial fibrillation in patients who received preoperative amiodarone and
      compare them to the incidence of atrial fibrillation in patients who did not received
      preoperative amiodarone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of post-operative atrial fibrillation</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital charges</measure>
    <time_frame>1 week on average</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of post-operative hospital stay</measure>
    <time_frame>1 week on average</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of other post-operative complications</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perioperative amiodarone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control arm, standard care with no perioperative amiodarone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Perioperative orally administered</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Perioperative oral amiodarone</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control arm, standard care</intervention_name>
    <description>Control</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resectable lung nodule or mass

        Exclusion Criteria:

          -  Allergy to amiodarone

          -  Currently taking amiodarone

          -  Documented atrial fibrillation within past 12 months

          -  Known pulmonary fibrosis

          -  Known hepatic dysfunction

          -  Thyroid disease

          -  2nd or 3rd degree heart block

          -  Severe SA node disease

          -  Bradycardia-induced syncope

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm M DeCamp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malcolm M DeCamp, MD</last_name>
    <phone>617-632-8386</phone>
    <email>mdecamp@bidmc.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm M DeCamp, MD</last_name>
      <phone>617-632-8386</phone>
      <email>mdecamp@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Malcolm M DeCamp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <lastchanged_date>May 5, 2008</lastchanged_date>
  <firstreceived_date>March 8, 2006</firstreceived_date>
  <responsible_party>
    <name_title>Malcolm DeCamp Jr., MD</name_title>
    <organization>BIDMC</organization>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Pulmonary resection</keyword>
  <keyword>Post-operative complications</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
